In a large phase 3 obesity trial (ACHIEVE-1), orforglipron at daily doses of 3, 12 and 36 mg caused approximately: Diarrhoea: 1926% of participants (vs 9% on placebo) Nausea: 1318% (vs 2% on placebo) Constipation: 817% (vs 4% on placebo) Vomiting: 514% (vs 1% on placebo) Across multiple studies, 617% of people stopped treatment because of side effects, mostly gut-related symptoms
Results showed that both L-glutathione or L-cysteine lightened skin on the upper forearm, and reduced the color of dark spots on the face
Beneficial in achieving lean mass
This gives everyone more time to negotiate a permanent solution, but the costs are no jokeexperts estimate it could end up costing Medicare billions of dollars every year based on how many people use it.
In partnership with Swipe Out Hunger, the brand is delivering both product donations and nutrition education to US universities, with the goal of improving access to high-protein snacks for students and athletes